Novo Nordisk’s Insulin Degludec/Liraglutide is Set to Become the Clinical Gold-Standard Among Fixed-Dose Combination Therapies for Type 2 Diabetes

July 7, 2014

Agents That Can Elicit Greater Weight Loss Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group

BURLINGTON, Mass., July 7, 2014 /PRNewswire/ — Decision Resources Group finds that Novo Nordisk’s fixed-dose combination (FDC) therapy insulin degludec/liraglutide (Xultophy, formerly known as IDegLira) is set to become the clinical gold-standard among FDCs used to treat patients with type 2 diabetes. The competitive advantages that this long-acting insulin analogue/glucagon-like peptide (GLP)-1 receptor agonist FDC has over other FDCs are due to the combined actions of the highly efficacious individual components on various measures of glycemic control.


Other key findings from the DecisionBase report entitled Type 2 Diabetes (Fixed-Dose Combinations): Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy?:

    --  Prescribing decisions: Surveyed U.S. and European endocrinologists agree
        that a therapy's ability to reduce glycated hemoglobin A1c (HbA1c) is
        the attribute that most influences their decisions regarding prescribing
        in type 2 diabetes.
    --  Key unmet needs: Greater reduction in body weight was highlighted by
        U.S. endocrinologists as the greatest unmet need relating to the
        treatment of type 2 diabetes. Interviewed thought leaders note that
        coadministration of a GLP-1 receptor agonist with an insulin has the
        potential to mitigate the weight gain associated with insulin treatment
        and are therefore enthusiastic about combining these treatments.
    --  Factors influencing formulary decisions: Surveyed U.S. payers indicate
        that improvements in the key efficacy attribute of greater reduction in
        body weight and the key safety attribute of greater reduction in
        incidence of cardiovascular adverse events will be chief drivers for
        formulary inclusion.

Comments from Decision Resources Group Analyst Tim Blackstock, M.B. Ch.B., M. Phil.:

    --  "Given that type 2 diabetes patients are often treated with several
        agents, FDCs are a way to improve convenience and compliance for
        patients with a high pill burden. The main drawback highlighted by
        interviewed thought leaders is the less-flexible titration offered by
        these combinations compared with individual agents."
    --  "While both surveyed physicians and payers highlight greater reductions
        in body weight as a key unmet need, the development of novel agents with
        improved efficacy in reducing HbA1c remains the greatest opportunity for
        pharmaceutical companies working in type 2 diabetes."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus